drug protocol number

22453

drug sponsor

Bayer Saudi Arabia LLC

drug study

ATC L01XE21, Protein kinase inhibitors, Regorafenib, Sorafenib,

drug trial site

King Faisal Specialist Hospital and Research Center (Jeddah)

drug status

Ongoing

drug phase